University of Oxford: Malaria trials

The registry lists 114 Malaria studies with University of Oxford as lead sponsor. 4 are open to participants now and 10 have results posted.

Early Phase 1 3Phase 1 47Phase 2 33Phase 3 13Phase 4 5No phase 38(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy AdultsNot yet recruitingNCT07470424Phase 1
• Clinical Study to Assess Minimum Mosquito Bites for P. Vivax Infection in Thai AdultsRecruitingNCT07257965Not applicable
• R21/MM Dosing, Presentations, and PreservativesNot yet recruitingNCT07194668Phase 4
• Surveillance of AMR in DRCRecruitingNCT06821282
• A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UKTerminatedNCT05400746Early Phase 1Results posted
• Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Vivax Malaria Vaccine Candidate PvDBPII in Matrix M1CompletedNCT04201431Phase 1/2Results posted
• VAC071: A Study to Assess Efficacy of the ChAd63/MVA PvDBP VaccinesCompletedNCT04009096Phase 2Results posted
• VAC069: A Study of Blood-stage Controlled Human P. Vivax InfectionCompletedNCT03797989Early Phase 1Results posted
• Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and VietnamCompletedNCT03355664Phase 3Results posted
• Malaria Vaccine Safety and Immunogenicity Study in Healthy AdultsCompletedNCT02992119Phase 2Results posted
• A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine CandidateCompletedNCT02927145Phase 1/2Results posted
• A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 AdjuvantCompletedNCT02925403Phase 1/2Results posted
• A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1CompletedNCT02572388Phase 1Results posted
• Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and SyringeCompletedNCT01465048Not applicableResults posted
• A Study to Compare Two Dosing Regimens for a New Malaria VaccineActive, not recruitingNCT06141057Phase 1
• A Study to Assess the Safety and Effectiveness of Two Experimental Malaria VaccinesCompletedNCT05978037Phase 1/2
• Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIVCompletedNCT05385510Phase 1
• A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK AdultsActive, not recruitingNCT05385471Early Phase 1
• Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI VaccinesCompletedNCT05155579Phase 1
• Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable ArtesunateCompletedNCT05140278Phase 2
• Monitoring Pregnant Women for Antimalarial Drug ResistanceCompletedNCT05072613
• Village Malaria Worker ExpansionCompletedNCT05045547
• A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in TanzaniaCompletedNCT04788862Not applicable
• R21/Matrix-M in African Children Against Clinical MalariaActive, not recruitingNCT04704830Phase 3
• Star Homes Project 2CompletedNCT04529434Not applicable
• Characterizing Humoral Immune Response to Mosquito BitesCompletedNCT04478370Not applicable
• Safety and Immunogenicity of RH5.1/Matrix-M in Adults and Infants Living in TanzaniaCompletedNCT04318002Phase 1
• Controlled Human Malaria Infection Transmission Model - Phase ASuspendedNCT04280692Phase 1/2
• Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.TerminatedNCT04271306Phase 1
• Lung Ultrasound in Children With Severe MalariaCompletedNCT04176029
• VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M VaccineTerminatedNCT04130282Phase 1
• Mass Screening and Treatment for Reduction of Falciparum MalariaCompletedNCT04093765Not applicable
• Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambodia)CompletedNCT04041973Not applicable
• VAC 072-An Efficacy Study of R21/MM in Different Dose SchedulesCompletedNCT03970993Phase 1/2
• A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan AdultsTerminatedNCT03947190Phase 2
• A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)CompletedNCT03939104Phase 3
• VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum InfectionCompletedNCT03906474Not applicable
• An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAPCompletedNCT03707353Phase 1/2
• Monitoring of Perfusion in Sepsis and MalariaCompletedNCT03641534
• A Study to Determine if a New Malaria Vaccine is Safe and Induces Immunity Among Kenyan Adults, Young Children and InfantsCompletedNCT03580824Phase 1/2
• Evaluation of a Digital Microscope for MalariaCompletedNCT03512678
• Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan ChildrenCompletedNCT03452475Phase 3
• Malaria Genetic SurveillanceStatus unknownNCT03384498
• Malaria Genetic Surveillance in CambodiaCompletedNCT03384472
• Study of Controlled Human Plasmodium Vivax InfectionCompletedNCT03377296Not applicable
• A Retrospective Study of Severe Plasmodium VivaxCompletedNCT03307369
• Prevalence Survey of Antimalarial Drug Resistance MarkersCompletedNCT03217851
• A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2CompletedNCT03203421Phase 1/2
• ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. FalciparumCompletedNCT03132402
• A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of AdministrationCompletedNCT03084289Phase 1
• Epidemiology of Malaria in Ubon Ratchathani, ThailandStatus unknownNCT02991963
• Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)CompletedNCT02932072
• A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAPCompletedNCT02905019Phase 1/2
• Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance MarkersCompletedNCT02895568
• G6PD Assessment Before Primaquine for Radical Treatment of Vivax MalariaCompletedNCT02876549Phase 4
• P.Vivax Treatment TrialCompletedNCT02802813Phase 1/2
• Child Follow-up Until 2 YearsCompletedNCT02800109
• Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)Status unknownNCT02739763Phase 1
• Artemisinin Resistance In Malaria Treated With IV ArtesunateWithdrawnNCT02640495
• A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01BCompletedNCT02600975Phase 1
• A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313CompletedNCT02532049Phase 1
• Bio-availability of Rectal Artesunate in Children With Severe Falciparum MalariaCompletedNCT02492178Phase 2
• Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern MyanmarWithdrawnNCT02461186Phase 2/3
• A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)CompletedNCT02453308Phase 2/3
• Severe and Cerebral Malaria Investigated Through Host MetabolomicsCompletedNCT02451904
• Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic MarkersCompletedNCT02427360
• Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum MalariaCompletedNCT02389439Phase 2
• A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,SCompletedNCT02252640Phase 1/2
• A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5CompletedNCT02181088Phase 1
• Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With MalariaCompletedNCT02092766Phase 4
• A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian InfantsCompletedNCT02083887Phase 1
• A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum MalariaCompletedNCT02044198Phase 1/2
• Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 DayCompletedNCT02020330Phase 3
• Optimal Fluid Management in Adult Severe MalariaCompletedNCT01936766
• Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in PregnancyCompletedNCT01916954Phase 3
• Malaria Survey in the Tak Province Refugee CampsCompletedNCT01902797Not applicable
• A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,SCompletedNCT01883609Phase 1/2
• Targeted Chemo-elimination (TCE) of MalariaCompletedNCT01872702Not applicable
• Phase Ia Study of ChAd63/MVA PvDBPCompletedNCT01816113Phase 1
• IMPROV (Improving the Radical Cure of Vivax Malaria)CompletedNCT01814683Not applicable
• Primaquine Pharmacokinetics in Lactating Women and Their InfantsCompletedNCT01780753Phase 1
• A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1CompletedNCT01739036Phase 1/2
• SPK Study in AfghanistanCompletedNCT01707199Not applicable
• Adjuvanting Viral Vectored Malaria Vaccines With Matrix MCompletedNCT01669512Phase 1
• Efficacy of Malaria Vaccines in Kenyan AdultsCompletedNCT01666925Phase 2
• Efficacy of Candidate Malaria Vaccines in Senegalese AdultsCompletedNCT01658696Phase 2
• Paracetamol Effect on Oxidative Stress and Renal Function in Severe MalariaCompletedNCT01641289Not applicable
• A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina FasoCompletedNCT01635647Phase 1/2
• A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine CandidatesCompletedNCT01623557Phase 1/2
• AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic AreaCompletedNCT01450293Phase 1
• Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CSCompletedNCT01450280Phase 1
• Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic AreasCompletedNCT01379430Phase 1
• AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic AreaCompletedNCT01373879Phase 1
• Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAPCompletedNCT01364883Phase 1
• Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909CompletedNCT01351948Phase 1
• Tracking Resistance to Artemisinin (TRAC)CompletedNCT01350856Phase 4
• Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax MalariaCompletedNCT01288820Phase 3
• Estimating the Risk of Plasmodium Vivax Relapses in AfghanistanCompletedNCT01178021Phase 4
• Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAPCompletedNCT01142765Phase 1/2
• Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum MalariaCompletedNCT01115439